Relationship between hemoglobin glycation index and risk of hypoglycemia in type 2 diabetes with time-in-range in target

doi:10.4239/wjd.v15.i10.2058

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-4)

Tables (1-3)

Sum=2

Oct 15, 2024 (publication date) through Sep 26, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Diabetes. Oct 15, 2024; 15(10): 2058-2069
Published online Oct 15, 2024. doi: 10.4239/wjd.v15.i10.2058

Table 1 Clinical characteristics of study participants

Characteristic	Total	HGI < 0.5	HGI ≥ 0.5	P value
Participants, n (%)	129	72 (56)	57 (44)
Age (years), mean ± SD	54.84 ± 12.56	53.33 ± 12.28	56.75 ± 12.75	0.414
Female	70 (54)	35 (49)	35 (61)	0.148
BMI (kg/m²)	24.52 ± 3.11	24.33 ± 12.14	24.76 ± 6.62	0.392
Duration of diabetes (months), medians (IQR)	73 (109.5)	73 (85.17)	97.33 (127.77)	0.287
Diabetes therapy, n (%)
Diet only	25 (19)	18 (25)	7 (12)	0.077
Sulfonylurea	21 (16)	11 (15)	10 (18)	0.812
Metformin	58 (45)	27 (38)	31 (54)	0.075
α-glucosidase inhibitor	33 (26)	18 (25)	15 (26)	0.865
DPP4 inhibitor	28 (22)	18 (25)	10 (18)	0.391
SGLT-2 inhibitor	5 (4)	3 (4)	2 (4)	0.848
CSII/MDI	35 (27)	15 (21)	20 (35)	0.071
SBP (mmHg), mean ± SD	127.35 ± 14.09	126.22 ± 13.51	128.77 ± 14.79	0.375
DBP (mmHg), mean ± SD	80.84 ± 9.19	79.79 ± 8.06	82.18 ± 10.37	0.104
TC (mmol/L), mean ± SD	4.39 ± 1.07	4.33 ± 1.02	4.46 ± 1.13	0.790
TG (mmol/L), mean ± SD	1.63 ± 1.26	1.63 ± 1.48	1.64 ± 0.93	0.285
LDL-C (mmol/L), mean ± SD	2.68 ± 0.89	2.60 ± 0.86	2.78 ± 0.92	0.275
HDL-C (mmol/L), mean ± SD	1.13 ± 0.48	1.19 ± 0.58	1.07 ± 0.30	0.216
Laboratory HbA1c (%), mean ± SD	6.63 ± 1.27	5.95 ± 0.71	7.43 ± 1.30	< 0.001^a
Hemoglobin (g/L), mean ± SD	133.84 ± 14.68	136.33 ± 13.21	131.70 ± 15.92	0.085
Hemotocrit (%), mean ± SD	0.40 ± 0.04	0.41 ± 0.04	0.39 ± 0.05	0.042^a
Red cell distribution width (%), mean ± SD	0.13 ± 0.01	0.13 ± 0.01	0.13 ± 0.01	0.556
Hypoglycemia, n (%)	49	10 (14)	39 (67)	< 0.001^a

^aP < 0.05, compared with the values from two groups.

HGI: Hemoglobin glycation index; BMI: Body mass index; DPP4: Dipeptidyl peptidase-4; SGLT-2: Sodium-glucose co-transporter type 2; CSII: Continuous subcutaneous insulin infusion; MDI: Multiple daily injection; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; TC: Total cholesterol; TG: Triglyceride; LDL-C: Low density lipoprotein cholesterol; HDL-C: High density lipoprotein cholesterol; HbA1c: Hemoglobin A1c; IQR: Interquartile range.

Table 2 Continuous glucose monitoring parameters

Characteristic	Total	HGI < 0.5	HGI ≥ 0.5	P value
Participants, n (%)	129	72 (56)	57 (44)
GMI (%), mean ± SD	6.09 ± 0.67	6.11 ± 0.70	6.06 ± 0.63	0.752
Average glucose (mmol/L), mean ± SD	7.11 ± 1.06	7.13 ± 1.10	7.08 ± 1.02	0.885
SDBG (mmol/L), mean ± SD	1.67 ± 0.64	1.59 ± 0.63	1.77 ± 0.64	0.961
CV (%), mean ± SD	22.89 ± 7.65	21.41 ± 6.78	24.76 ± 8.31	0.017^a
MAGE (mmol/L), mean ± SD	4.08 ± 1.81	3.88 ± 1.72	4.35 ± 1.91	0.742
LAGE (mmol/L), mean ± SD	8.86 ± 3.03	8.26 ± 2.89	9.63 ± 3.06	0.005^a
MODD (mmol/L), medians (IQR)	1.40 (0.70)	1.30 (0.50)	1.50 (0.60)	0.024^a
TIR (% of time 39-10 mmol/L), medians (IQR)	90 (17)	93.50 (13)	86 (16)	0.002^a
TBR (% of time < 3.9 mmol/L), medians (IQR)	1 (5)	0 (2)	2 (11)	< 0.001^a
TAR (% of time > 10 mmol/L), medians (IQR)	6 (13)	4.50 (11)	8 (12)	0.068

^aP < 0.05, compared with the values from two groups.

HGI: Hemoglobin glycation index; GMI: Glucose management indicator; SDBG: Standard deviation blood glucose; CV: Coefficient of variation; MAGE: Mean amplitude of glucose excursion; LAGE: Largest amplitude of glycemic excursions; MODD: Mean of daily differences; TIR: Time in range; TBR: Time below range; TAR: Time above range.

Table 3 Clinical markers of glycemia variables for hypoglycemia analyzed by univariate and multiple logistic regression analyses

	Univariate logistic regression			Multiple logistic regression
	χ²	P value	OR (95%CI)	Wald χ²	P value	OR (95%CI)
Sex (female/male)	0.82	0.37	0.73 (0.36-1.45)
Age	4.25	0.04^a	0.42 (0.19-0.96)
BMI	0.09	0.77	1.11 (0.55-2.25)
Laboratory HbA1c	0.36	0.55	0.81 (0.41-1.62)
Hemotocrit	1.81	0.18	1.75 (0.78-3.95)
MBG	4.26	0.04^a	0.45 (0.21-0.96)	9.05	< 0.01^a	0.17 (0.05-0.54)
SDBG	9.74	< 0.01^a	3.44 (1.58-7.47)	5.30	0.02^a	5.37 (1.28-22.46)
LAGE	3.41	0.07	7.56 (0.88-64.67)
MAGE	6.95	0.01^a	2.62 (1.28-5.35)
MODD	0.32	0.57	1.36 (0.46-4.01)
HGI	6.98	< 0.01^a	2.65 (1.29-5.44)	4.65	0.03^a	2.46 (1.09-5.58)
Use of insulin and/or sulfonylurea	0.30	0.58	1.22 (0.60-2.51)

^aP < 0.05.

OR: Odds ratio; CI: Confidence interval; BMI: Body mass index; HbA1c: Hemoglobin A1c; MBG: Mean blood glucose; SDBG: Standard deviation blood glucose; LAGE: LAGE: Largest amplitude of glycemic excursions; MAGE: Mean amplitude of glucose excursion; MODD: Mean of daily differences; HGI: Hemoglobin glycation index.

Citation: Lin BS, Liu ZG, Chen DR, Yang YL, Yang DZ, Yan JH, Zeng LY, Yang XB, Xu W. Relationship between hemoglobin glycation index and risk of hypoglycemia in type 2 diabetes with time-in-range in target. World J Diabetes 2024; 15(10): 2058-2069
URL: https://www.wjgnet.com/1948-9358/full/v15/i10/2058.htm
DOI: https://dx.doi.org/10.4239/wjd.v15.i10.2058